

Maximising the Metastatic Breast Cancer Treatment Paradigm and Looking Ahead



SATURDAY, 14 SEPTEMBER 2024 | 13:00–14:30 CEST

Salamanca Auditorium - Hall 5, Fira Barcelona Gran Via, Barcelona, Spain

OVERVIEW

Join our esteemed faculty Drs Cortés, Rugo, Criscitiello and Tolaney in this year's symposium for an engaging and interactive discussion on CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer, focusing on expert commentary of key clinical data and current clinical practices with related clinical cases. Gain practical knowledge on how best to complement clinical trial data with real-world evidence for a shared decision-making approach with patients. Attendees, who will have the opportunity to explore these complex issues in an interactive Q&A session, will also hear stimulating conversations on the potential treatment opportunities in metastatic breast cancer within the current evolving treatment landscape.

SPEAKERS



Javier Cortés, MD, PhD
International Breast Cancer Center (IBCC)
Barcelona, Spain



Hope S. Rugo, MD, FASCO
University of California
San Francisco (UCSF),
San Francisco, California, United States



Carmen Criscitiello, MD, PhD
University of Milan
Milan, Italy



Sara M. Tolaney, MD, MPH
Susan F. Smith Center for
Women's Cancers
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

AGENDA

Welcome and Introduction

Javier Cortés, Barcelona, Spain

Interactive Grand Rounds: Clinical Decision-Making in 1L HR+/HER2- MBC

Javier Cortés, Barcelona, Spain
Hope S. Rugo, San Francisco, USA
Carmen Criscitiello, Milan, Italy

What's on the Horizon for Patients With MBC?

Sara M. Tolaney, Boston, USA
Carmen Criscitiello, Milan, Italy

Panel Discussion and Audience Q&A

All faculty

Closing Remarks

Javier Cortés, Barcelona, Spain